As of Wednesday close, Amneal Pharmaceuticals Inc.’s (NYSE:AMRX) stock was down -$0.25, moving down -6.39 percent to $3.66. The average number of shares traded per day over the past five days has been 1,278,540 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.57 fall in that time frame. In the last twenty days, the average volume was 1,283,030, while in the previous 50 days, it was 1,199,814.
Since last month, AMRX stock rose 12.96%. Shares of the company fell to $2.99 on 07/28/23, the lowest level in the past month. A 52-week high of $4.74 was reached on 08/07/23 after having rallying from a 52-week low of $1.24. Since the beginning of this year, AMRX’s stock price has risen by 83.92% or $1.67, and marked a new high 24 times. However, the stock has declined by -22.78% since its 52-week high.
AMRX stock investors should be aware that Amneal Pharmaceuticals Inc. (AMRX) stock had its last reported insider trading activity 6 days ago on Aug 11. BOYER ANDREW S, the Executive Vice President of the company, disposed of 29,302 shares for $4.13 on Aug 11. It resulted in a $120,921 divestment by the insider. TPG GP A, LLC sold 3,884,600 shares at an average price of $2.34 on Dec 12. The insider now owns 12,328,767 shares following the transaction.
Valuation Metrics
The stock’s beta is 1.29. Besides these, the trailing price-to-sales (P/S) ratio of 0.52, the price-to-book (PB) ratio of 1.77, and the price-to-cash flow ratio of 10.47 may also be considered.
Financial Health
In the three months ended June 29, Amneal Pharmaceuticals Inc.’s quick ratio stood at 1.10, while its current ratio was 1.80, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 8.33, and the total debt-to-equity ratio was 8.81. On the profitability front, the trailing twelve-month gross margin is 35.20% percent. In the year ended June 29, EBITDA margin amounted to 19.92%, whereas operating margins totaled 8.40%. Based on annual data, AMRX earned $784.71 million in gross profit and brought in $2.21 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -3.30%. Return on equity (ROE) for the past 12 months was -0.70%.
In Amneal Pharmaceuticals Inc.’s quarter-end financial report for June 29, it reported total debt of $2.55 billion. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. AMRX’s revenue rose 16.93% to $557.54 million during the quarter, while net income inched up to $599.02 million. While analysts expected Amneal Pharmaceuticals Inc. to report $0.11 quarterly earnings, the actual figure was $0.19 per share, beating the consensus estimate by 72.70%. During the quarter, the company generated $139.66 million in EBITDA. The liabilities of Amneal Pharmaceuticals Inc. were 3.55 billion at the end of its most recent quarter ended June 29, and its total debt was $2.86 billion. The value of shareholders’ equity is $306.31 million.
Technical Picture
This quick technical analysis looks at Amneal Pharmaceuticals Inc.’s (AMRX) price momentum. With a historical volatility rate of 135.41%, the RSI 9-day stood at 46.82% on 16 August.
With respect to its five-day moving average, the current Amneal Pharmaceuticals Inc. price is down by -13.48% percent or -$0.57. At present, AMRX shares trade +13.66% above its 20-day simple moving average and +179.39% percent above its 100-day simple moving average. However, the stock is currently trading approximately +42.97% above its SMA50 and +64.13% above its SMA200.
Stochastic coefficient K was 48.19% and Stochastic coefficient D was 54.16%, while ATR was 0.27. Given the Stochastic reading of 38.29% for the 14-day period, the RSI (14) reading has been calculated as 52.50%. As of today, the MACD Oscillator reading stands at -0.29, while the 14-day reading stands at 0.03.
Analyst Ratings
Amneal Pharmaceuticals Inc. (AMRX) has been rated Overweight by analysts. According to 1 brokerage firm, AMRX is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Amneal Pharmaceuticals Inc. stock as buy, with 3 recommending it as overweight.
With a median target price of $5.00, the current consensus forecast for the stock is $5.00 – $6.00. Based on these forecasts, analysts predict Amneal Pharmaceuticals Inc. (AMRX) will achieve an average price target of $5.25.
